Elite Pharmaceuticals Inc
OTC:ELTP

Watchlist Manager
Elite Pharmaceuticals Inc Logo
Elite Pharmaceuticals Inc
OTC:ELTP
Watchlist
Price: 0.5425 USD 2.4% Market Closed
Market Cap: 579.6m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ELTP stock under the Base Case scenario is 0.2531 USD. Compared to the current market price of 0.5425 USD, Elite Pharmaceuticals Inc is Overvalued by 53%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ELTP Relative Value
Base Case
0.2531 USD
Overvaluation 53%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.9
P/S
P/S
Price to Sales
6.9
vs History
11
vs Industry
20
Median 3Y
3
Median 5Y
2.3
Industry
2.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
33
Median 3Y
5.9
Median 5Y
6.9
Industry
22.2
More Details
77.7
P/OCF
P/OCF
Price to OCF
77.7
vs History
17
vs Industry
5
Median 3Y
15.4
Median 5Y
15.4
Industry
17.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
2
Median 3Y
-3.5
Median 5Y
3
Industry
23.7
More Details
10.8
P/B
P/B
Price to Book Value
10.8
vs History
11
vs Industry
4
Median 3Y
3.1
Median 5Y
3.1
Industry
2.3
More Details
6.9
EV/S
EV/S
Enterprise Value to Sales
6.9
vs History
11
vs Industry
19
Median 3Y
3
Median 5Y
2.2
Industry
2.8
More Details
14.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.4
vs History
11
vs Industry
13
Median 3Y
6.4
Median 5Y
4.7
Industry
5.6
More Details
24.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
24.7
vs History
15
vs Industry
10
Median 3Y
14
Median 5Y
14
Industry
13.3
More Details
27.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
27.2
vs History
28
vs Industry
10
Median 3Y
17
Median 5Y
14.6
Industry
16.5
More Details
77.3
EV/OCF
EV/OCF
Enterprise Value to OCF
77.3
vs History
17
vs Industry
5
Median 3Y
14.2
Median 5Y
14.2
Industry
15.6
More Details
116.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
116.9
vs History
22
vs Industry
3
Median 3Y
9.3
Median 5Y
12.6
Industry
17.9
More Details
7
EV/IC
EV/IC
Enterprise Value to IC
7
vs History
9
vs Industry
12
Median 3Y
2.4
Median 5Y
2.2
Industry
2
More Details

Multiples Across Competitors

ELTP Competitors Multiples
Elite Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Elite Pharmaceuticals Inc
OTC:ELTP
579.6m USD 6.9 -134.3 24.7 27.2
US
Eli Lilly and Co
NYSE:LLY
663.9B USD 12.5 48.1 28.5 31
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
424.9B USD 4.7 18.8 14.3 18.8
CH
Roche Holding AG
SIX:ROG
203.6B CHF 3.4 24.6 9.3 10.8
UK
AstraZeneca PLC
LSE:AZN
179.8B GBP 4.3 29.4 113.3 169.4
CH
Novartis AG
SIX:NOVN
192.2B CHF 4.3 17.5 10.5 13.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13 9.5 10.6
US
Merck & Co Inc
NYSE:MRK
211.9B USD 3.3 12.9 8.3 9.9
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
142.9B USD 2.2 13.3 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Elite Pharmaceuticals Inc
OTC:ELTP
Average P/E: 22.2
Negative Multiple: -134.3 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.8
27%
0.7
CH
Roche Holding AG
SIX:ROG
24.6
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.4
36%
0.8
CH
Novartis AG
SIX:NOVN
17.5
16%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13
18%
0.7
US
Merck & Co Inc
NYSE:MRK
12.9
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.3
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Elite Pharmaceuticals Inc
OTC:ELTP
Average EV/EBITDA: 396.7
24.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.5
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.3
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.3
10%
11.3
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
13%
0.7
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Elite Pharmaceuticals Inc
OTC:ELTP
Average EV/EBIT: 1 703.3
27.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.8
14%
1.3
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.4
23%
7.4
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.9
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
9%
1.1

See Also

Summary
ELTP intrinsic value, competitors valuation, and company profile.
DCF Valuation
ELTP stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ELTP stock valuation using valuation multiples.
Wall Street Estimates
ELTP price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ELTP stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 275,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.